Eschenbach Andrew Von Sells 12,500 Shares of Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb Corporation (NYSE:BLCO) Director Eschenbach Andrew Von sold 12,500 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $16.50, for a total value of $206,250.00. Following the transaction, the director owned 69,792 shares in the company, valued at $1,151,568. This represents a 15.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Bausch + Lomb Price Performance

Shares of Bausch + Lomb stock traded up $0.02 on Monday, reaching $16.80. The company’s stock had a trading volume of 324,953 shares, compared to its average volume of 443,694. The company has a market capitalization of $6.00 billion, a P/E ratio of -35.00, a PEG ratio of 0.54 and a beta of 0.55. Bausch + Lomb Corporation has a 52-week low of $13.53 and a 52-week high of $18.92. The stock has a 50-day moving average price of $16.05 and a 200-day moving average price of $16.39. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.79.

Analyst Upgrades and Downgrades

BLCO has been the subject of a number of research reports. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Evercore set a $17.00 price objective on Bausch + Lomb in a report on Monday, July 6th. Citigroup boosted their price objective on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on Bausch + Lomb in a report on Thursday, April 30th. Finally, HC Wainwright raised their target price on Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $18.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its stake in Bausch + Lomb by 3.9% during the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock worth $320,000 after acquiring an additional 711 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Bausch + Lomb by 38.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock worth $64,000 after purchasing an additional 1,039 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Bausch + Lomb by 5.3% during the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock worth $364,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after purchasing an additional 1,403 shares during the period. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.